Загрузка...
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma
Pembrolizumab is a monoclonal antibody directed against PD-1 that is US FDA approved for treatment of advanced PD-L1 positive gastric and gastroesophageal junction adenocarcinoma in patients who have progressed on at least two prior lines of chemotherapy. This article summarizes the clinical evidenc...
Сохранить в:
| Опубликовано в: : | Future Oncol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Future Medicine Ltd
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5827797/ https://ncbi.nlm.nih.gov/pubmed/29094609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2017-0436 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|